This article was originally published in Clinica
Technology for Industry, the UK consultancy specialising in micro- and nanotechnology (MNT), has published the 2005 edition of its MNT in Healthcare and Lifesciences market sector report. It includes a market overview, industry size and trends, and technological developments, featuring the following specialisms: cardiac pacemakers and implantable devices; blood pressure sensors; hearing aids and cochlear implants; blood analysis; catheters, endoscopes and minimally invasive surgery; drug delivery systems; DNA analysis and lab-on-a-chip; and MNT applications in sensors/actuators. The MNT market is already worth $5bn and is projected to grow to $11m within three years, the Ely, Cambridgeshire company (www.tfi-ltd.co.uk) believes.
You may also be interested in...
Towa’s US-based Breckenridge is aiming for exclusivity with its generic version of Amgen’s Kyprolis – developed with partner Natco Pharma – after obtaining one of the first approvals for several strengths of the treatment for relapsed or refractory multiple myeloma.
As Nestlé continues to expand its presence in the VMS market it will not take a brand popular in one country and “force” that name on consumers in a different part of the world, says CEO Mark Schneider.
Lupin has claimed a first with a UK approval for a rival to Fostair. The Indian company has told Generics Bulletin that it is planning to roll out the Luforbec branded generic later this year.